There is no doubt clinical trials is a long a process , but...

There is no doubt clinical trials is a long a process , but going over released information over the years , in my opinion , Cellmid seemed much closer to human trials  .

For example whatever happen to  the below collaboration  .

Cellmid (ASX:CDY) has selected Biotecnol SA subsidiary Rodon Biologics as the manufacturing partner for its humanised anti-midkine (MK) antibody CAB102 for clinical trials in multiple oncology indications.

Biotecnol has successfully completed numerous drug product and process development projects for 14 years.

This will save six months in ‘time to clinic’ for CAB102 with the clinical program on track for first in human studies in early 2015.